Top Markets
#1 EXOD EXOD +56.80%
#2 Glidr Glidr +38.25%
#3 Solv Protocol xSolvBTC Solv Protocol xSolvBTC +22.79%
#4 Cysic Cysic +18.33%
#5 Nockchain Nockchain +17.91%
#6 Bedrock Bedrock +17.41%
#7 Velvet Velvet +14.00%
#8 Perle Perle +13.44%
#9 Fabric Protocol Fabric Protocol +12.53%
#10 Versatize Coin Versatize Coin +12.50%
Coin of the day
EXOD EXOD
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Intellipharmaceutics International Inc. Intellipharmaceutics International Inc.

Intellipharmaceutics International Inc.

IPCI
Classement en actions #37527
Intellipharmaceutics International Inc., founded in Toronto, Canada, in 1998,... Intellipharmaceutics International Inc., founded in Toronto, Canada, in 1998, is a pharmaceutical company that focuses on the research, development, and manufacturing of innovative and generic controlled-release and targeted-release oral solid dosage medications, primarily for the United States market. The company leverages its patented Hypermatrix technology to create advanced drug delivery systems, an array of product candidates, and a robust pipeline across diverse therapeutic areas, including neurological, cardiovascular, gastrointestinal, diabetes, and pain management conditions. Its current product portfolio includes extended-release formulations like Focalin XR for hyperactivity disorder, Keppra XR for partial onset seizures, Effexor XR to treat depression, and Protonix for gastroesophageal reflux disease. Other offerings feature Glucophage XR for type 2 diabetes, Seroquel XR for schizophrenia and mood disorders, Lamictal XR for epilepsy, Pristiq for depression, Coreg CR for heart failure and hypertension, and Ranexa for chronic angina. Furthermore, Intellipharmaceutics is actively developing additional controlled-release drugs such as OxyContin for pain relief and Regabatin XR for neuropathic pain management. The company operates under a license and commercialization agreement with Par Pharmaceutical Inc.
Prix de l'action
$0.05897422
Dernière synchronisation: 2024-04-02
Capitalisation boursière
$1.64M
Changement (1 jour)
0.07%
Changement (1 an)
0.00%
Pays
CA
Échange Intellipharmaceutics International Inc. (IPCI)

Catégorie

Healthcare
Bénéfices pour Intellipharmaceutics International Inc. (IPCI)
Bénéfices en 2026 TTM : 0
Selon les derniers rapports financiers de Intellipharmaceutics International Inc., les bénéfices actuels de l'entreprise sont de 0. En 2026, l'entreprise a réalisé un bénéfice de 0, égal à celui de 2026 qui était de 0. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Intellipharmaceutics International Inc. de 2026 à 2026
Bénéfices à la fin de chaque année
Année Bénéfices Changez
Pas assez de données pour les dates fournies.
Bénéfices des entreprises similaires ou concurrentes
Entreprise Bénéfices Différence de bénéfices Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE